Carolinas Wealth Consulting’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-524
Closed -$52.9K 114
2025
Q1
$52.9K Sell
524
-2
-0.4% -$201 0.01% 344
2024
Q4
$47K Sell
526
-109
-17% -$9.6K 0.01% 371
2024
Q3
$53.2K Sell
635
-98
-13% -$7.72K 0.01% 352
2024
Q2
$56.4K Buy
733
+44
+6% +$3.22K 0.01% 349
2024
Q1
$47.2K Sell
689
-24
-3% -$1.54K 0.01% 385
2023
Q4
$41.2K Sell
713
-2
-0.3% -$107 0.01% 363
2023
Q3
$36.6K Buy
715
+10
+1% +$524 0.01% 349
2023
Q2
$38.1K Buy
705
+674
+2,174% +$35.2K 0.01% 388
2023
Q1
$1.55K Hold
31
﹤0.01% 840
2022
Q4
$1.43K Sell
31
-100
-76% -$4.33K ﹤0.01% 851
2022
Q3
$5K Hold
131
﹤0.01% 652
2022
Q2
$5K Hold
131
﹤0.01% 648
2022
Q1
$6K Hold
131
﹤0.01% 673
2021
Q4
$6K Hold
131
﹤0.01% 681
2021
Q3
$6K Hold
131
﹤0.01% 646
2021
Q2
$6K Hold
131
﹤0.01% 669
2021
Q1
$5K Hold
131
﹤0.01% 697
2020
Q4
$5K Sell
131
-1,276
-91% -$46K ﹤0.01% 641
2020
Q3
$54K Buy
1,407
+1,276
+974% +$49.2K 0.02% 268
2020
Q2
$5K Buy
+131
New +$4.72K ﹤0.01% 390

Other funds holding BSX

Carolinas Wealth Consulting's BSX Position: Q2 2025 in Review

Carolinas Wealth Consulting sold out of Boston Scientific (BSX) in Q2 2025, closing a stake of 524 shares — an estimated $52.9K sold.

Carolinas Wealth Consulting first reported a position in BSX in Q2 2020 and held it in 20 quarters. The position peaked at $56.4K in Q2 2024. 1,687 funds tracked by Wall St. Rank hold BSX as of Q2 2025.

  • Carolinas Wealth Consulting reported no remaining Boston Scientific position as of Q2 2025 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 524 Boston Scientific shares in Q2 2025, an estimated $52.9K.
  • Carolinas Wealth Consulting first reported a position in Boston Scientific in Q2 2020 and held it in 20 quarters.
  • Carolinas Wealth Consulting's Boston Scientific position peaked at $56.4K in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2025.

Based on Carolinas Wealth Consulting's 13F filing for Q2 2025.